roni mamluk phd  chiasma you are using an outdated browser please upgrade your browser to improve your experience jump to navigation roni mamluk phd roni mamluk phd joined chiasma’s board of directors in june  she previously served as the company’s chief development officer from march  to april  she served as chief executive officer from april  to march  and held various roles of increasing responsibility including chief operating officer and vice president research and development from  to april  she also served as a member of our board of directors from april  to march  since joining us dr mamluk has played a leading role in developing and is one of the primary inventors of our proprietary transient permeability enhancer or tpe technology platform she has also led the development of oral octreotide and ongoing improvements to our tpe platform dr mamluk joined us from adnexus therapeutics inc where she established and led nonclinical research and development dr mamluk received her ba and phd from the hebrew university she also participated in a postdoctoral fellowship at children’s hospitalharvard medical school in the field of angiogenesis director print roni mamluk chief development officer chiasma timesjavascript is disabled market profiles login sign up login sign up   edit person roni mamluk chief development officer at chiasma location israel add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop roni mamluk chief development officer at chiasma location israel add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop as one of the primary inventors of the transient permeability enhancer tpe® technology platform dr mamluk serves as chiasma’s chief development officer working to advance the company’s lead product octreotide capsules and expand its pipeline in the past years dr mamluk held several senior positions with chiasma most recently as ceo in these roles she led the development of octreotide capsules readying it for nda submission her leadership transformed chiasma into a dynamic drug development company primed for commercializing its first product dr mamluk joined chiasma in  as director of preclinical development prior to joining chiasma dr mamluk worked at adnexus therapeutics where she established and headed up preclinical research and development dr mamluk received a ba and a phd summa cum laude from the hebrew university and she held a postdoctoral fellowship at children’s hospitalharvard medical school in the field of angiogenesis  companies in career na related markets  colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags na topics of influence na na careers achievements investments related people edit view all roni mamlukcareer  mar chiasma chief development officer apr to mar chiasma ceo aug to apr chiasma coo apr to jul adnexus therapeutics principal scientist competencies edit view all roni mamlukeducation  the hebrew university animal sciences edit roni mamlukachievements and recognitions add milestone no milestones has been recorded for roni mamluk edit roni mamluklinks add link no links has been recorded for roni mamluk roni mamlukinvestmentsacquisitions no investments has been recorded for roni mamluk roni mamlukinvestments representing others no investment reps has been recorded for roni mamluk roni mamlukrelated people colleagues at chiasma william ludlam vice president of medical affairs aug mark fitzpatrick chief financial officer may mark leuchtenberger president and ceo mar dana gelbaum vp business development  commercial planning aug view all peers  barbara klencke chief development officer of pronai therapeutics steven gelone chief development officer of nabriva therapeutics ken bartizal chief development officer of cidara therapeutics steve wigginton chief development officer of evolent health lawrence friedhoff chief development officer of axovant sciences reinilde heyrman chief clinical development officer of bellerophon therapeutics view all roni mamlukrecommended market profiles healthcare ipo companies  or more employees  companies chiasma appoints roni mamluk phd to board of directors  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search see headlines for chma view print version more from globenewswire chiasma appoints roni mamluk phd to board of directors chiasma reports first quarter  results referenced stocks chma  rate it chiasma appoints roni mamluk phd to board of directors by globenewswire  june    am edt vote up a a a longtime chiasma executive also assumes director role with chiasma ltd its israeli subsidiary waltham mass june   globe newswire  chiasma inc nasdaqchma a clinicalstage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced that roni mamluk phd has been reappointed to chiasmas board of directors recently she also transitioned from her position as chief development officer to a parttime role as director of chiasmas israeli subsidiary it has been a pleasure to work with roni in my role as chairman since  said dave stack chairman of the board of chiasma for more than  years she has devoted herself to this company and to the pursuit of a better quality of life for patients with acromegaly in that time she played a leading role in inventing our proprietary transient permeability enhancer tpe technology platform and developing our octreotide capsules product candidate we greatly appreciate her service and dedication and we welcome her forthcoming contributions as she rejoins the board i firmly believe in chiasmas vision of delivering increased convenience comfort and the potential for better symptom control to patients with acromegaly mamluk said i look forward to serving in an oversight capacity on both the chiasma ltd and chiasma inc boards of directors we have accomplished much during my tenure with the company and i am excited to build on those achievements in the years to come in mamluks new director role she will act as head of development on a parttime basis she will also have ongoing oversight of the companys israeli operations mamluk previously served as chiasmas chief development officer from march  to april  she also was the companys chief executive officer from april  to march  she held various roles of increasing responsibility including chief operating officer and vice president research and development from  through  she also served as a member of chiasmas board of directors from april  to march  in her time with chiasma mamluk has played a leading role in developing and is one of the primary inventors of the companys proprietary tpe technology platform mamluk previously worked for adnexus therapeutics where she established and led nonclinical research and development she received her ba and phd from hebrew university she also participated in a postdoctoral fellowship at boston childrens hospital  harvard medical school in the field of angiogenesis about chiasma chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases employing its transient permeability enhancer tpe® technology platform chiasma seeks to develop oral medications that are currently available only as injections the company is conducting an international phase  clinical trial of octreotide capsules conditionally tradenamed mycapssa® for the maintenance treatment of adult acromegaly patients to support a potential submission of a marketing authorization application to the european medicines agency chiasma received a complete response letter crl from the us food and drug administration fda on april   regarding its new drug application nda for mycapssa in the united states chiasma is headquartered in the united states with a wholly owned subsidiary in israel mycapssa and tpe are registered trademarks of chiasma  forwardlooking statements this release contains forwardlooking statements within the meaning of the private securities litigation reform act of  any forwardlooking statements in this press release are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forwardlooking statements these risks and uncertainties include but are not limited to risks associated with the regulatory review and approval process generally risks associated with chiasmas phase  clinical trial to support regulatory approval of octreotide capsules in the eu risks associated with chiasma potentially conducting an additional randomized doubleblind and controlled phase  clinical trial of octreotide capsules in accordance with the fdas recommendation to support regulatory approval of mycapssa in the united states including risks related to the enrollment timing and associated expenses of any potential trial risks associated with chiasma pursuing a development pathway other than the path strongly recommended by the fda risks associated with the ability of the companys suppliers to pass future regulatory inspections risks associated with obtaining maintaining and protecting intellectual property risks associated with chiasmas ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties the risk that octreotide capsules if approved will not be successfully commercialized the risk of competition from currently approved therapies and from other companies developing products for similar uses risks associated with chiasmas ability to manage operating expenses andor obtain additional funding to support its business activities risks associated with chiasmas dependence on third parties and risks associated with defending any litigation including the risk that we incur more costs than we expect and uncertainty involving the outcome for a discussion of these and other risks and uncertainties and other important factors any of which could cause our actual results to differ from those contained in the forwardlooking statements see the section entitled risk factors in chiasmas annual report on form k for the year ended december   filed with the securities and exchange commission sec on march   and in subsequent filings with the securities and exchange commission all information in this press release is as of the date of the release and chiasma undertakes no duty to update this information unless required by law contact andrew blaziersharon merrill associates   chmainvestorrelationscom source chiasma inc this article appears in news headlines referenced stocks chma latest news video login please enable javascript to view the comments powered by realtidbits related stocks articles subscribe citizens  northern corp cznc exdividend date scheduled for july     am education realty trust inc edr exdividend date scheduled for july     am national retail properties nnn exdividend date scheduled for july     am closex signin existing nasdaqcom member log in here by signing into to the site using any of the thirdparty services above you agree to nasdaqcoms terms of use welcome back log in using your   account switch accounts highest rated articles of last week yatra attains leadership position in corporate travel with the merck and pfizer collaborate with corning to modernize  an indepth look at baidus bidu artificial intelligence aspirations petiq inc nasdaq petq to ring the nasdaq stock market opening south alabama property receives csx select site designation view all highest rated todays market activity nasdaq    ▲   djia    ▲   sp     ▲   data as of jul   try for free nasdaq livequotes platform view all upcoming earnings company expected report date aapl jul   odfl jul   fb jul   tsla aug   t jul   amzn jul   vz jul   ge jul   earnings calendar closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex chiasma appoints roni mamluk ph d to board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       chiasma appoints roni mamluk phd to board of directors tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs  longtime chiasma executive also assumes director role with chiasma ltd its israeli subsidiary waltham mass june   globe newswire  chiasma inc nasdaqchma a clinicalstage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced that roni mamluk phd has been reappointed to chiasma’s board of directors recently she also transitioned from her position as chief development officer to a parttime role as director of chiasma’s israeli subsidiary “it has been a pleasure to work with roni in my role as chairman since ” said dave stack chairman of the board of chiasma “for more than  years she has devoted herself to this company and to the pursuit of a better quality of life for patients with acromegaly in that time she played a leading role in inventing our proprietary transient permeability enhancer tpe technology platform and developing our octreotide capsules product candidate we greatly appreciate her service and dedication and we welcome her forthcoming contributions as she rejoins the board” “i firmly believe in chiasma’s vision of delivering increased convenience comfort and the potential for better symptom control to patients with acromegaly” mamluk said “i look forward to serving in an oversight capacity on both the chiasma ltd and chiasma inc boards of directors we have accomplished much during my tenure with the company and i am excited to build on those achievements in the years to come” in mamluk’s new director role she will act as head of development on a parttime basis she will also have ongoing oversight of the company’s israeli operations mamluk previously served as chiasma’s chief development officer from march  to april  she also was the company’s chief executive officer from april  to march  she held various roles of increasing responsibility including chief operating officer and vice president research and development from  through  she also served as a member of chiasma’s board of directors from april  to march  in her time with chiasma mamluk has played a leading role in developing and is one of the primary inventors of the company’s proprietary tpe technology platform mamluk previously worked for adnexus therapeutics where she established and led nonclinical research and development she received her ba and phd from hebrew university she also participated in a postdoctoral fellowship at boston children’s hospital  harvard medical school in the field of angiogenesis about chiasma chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases employing its transient permeability enhancer tpe® technology platform chiasma seeks to develop oral medications that are currently available only as injections the company is conducting an international phase  clinical trial of octreotide capsules conditionally tradenamed “mycapssa®” for the maintenance treatment of adult acromegaly patients to support a potential submission of a marketing authorization application to the european medicines agency chiasma received a complete response letter crl from the us food and drug administration fda on april   regarding its new drug application nda for mycapssa in the united states chiasma is headquartered in the united states with a wholly owned subsidiary in israel mycapssa and tpe are registered trademarks of chiasma forwardlooking statements this release contains “forwardlooking statements” within the meaning of the private securities litigation reform act of  any forwardlooking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forwardlooking statements these risks and uncertainties include but are not limited to risks associated with the regulatory review and approval process generally risks associated with chiasma’s phase  clinical trial to support regulatory approval of octreotide capsules in the eu risks associated with chiasma potentially conducting an additional randomized doubleblind and controlled phase  clinical trial of octreotide capsules in accordance with the fda’s recommendation to support regulatory approval of mycapssa in the united states including risks related to the enrollment timing and associated expenses of any potential trial risks associated with chiasma pursuing a development pathway other than the path strongly recommended by the fda risks associated with the ability of the company’s suppliers to pass future regulatory inspections risks associated with obtaining maintaining and protecting intellectual property risks associated with chiasma’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties the risk that octreotide capsules if approved will not be successfully commercialized the risk of competition from currently approved therapies and from other companies developing products for similar uses risks associated with chiasma’s ability to manage operating expenses andor obtain additional funding to support its business activities risks associated with chiasma’s dependence on third parties and risks associated with defending any litigation including the risk that we incur more costs than we expect and uncertainty involving the outcome for a discussion of these and other risks and uncertainties and other important factors any of which could cause our actual results to differ from those contained in the forwardlooking statements see the section entitled “risk factors” in chiasma’s annual report on form k for the year ended december   filed with the securities and exchange commission sec on march   and in subsequent filings with the securities and exchange commission all information in this press release is as of the date of the release and chiasma undertakes no duty to update this information unless required by law contact andrew blazier sharon merrill associates   chmainvestorrelationscom read at biospacecom related news chiasma enforces jobcutting scheme axing a further  of workforce aziyo biologics banks some cash and former osiris osir exec as its new ceo struggling chiasma chops  of workforce after fda drug rejection effective immediately bristolmyers squibb bmy exec to take the reins at kleo chiasma chief says firm may challenge fda over raredisease drug rejection what would  industry icons do differently if given the chance to be ceo again chiasma crashes on fda drug rejection of mycapssa alexion alxn poaches biogen biibs longtime cfo chiasma reviews  accomplishments and outlines core objectives for  struggling teva teva wants to overhaul board by nominating  new directors please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • chiasma inc   • biotechpharma  personnel                 chiasma appoints roni mamluk phd to board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street chiasma appoints roni mamluk phd to board of directors globenewswire jun    am edt waltham mass june   globe newswire  chiasma inc nasdaqchma a clinicalstage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced that roni mamluk phd has been reappointed to chiasmas board of directors recently she also transitioned from her position as chief development officer to a parttime role as director of chiasmas israeli subsidiary it has been a pleasure to work with roni in my role as chairman since  said dave stack chairman of the board of chiasma for more than  years she has devoted herself to this company and to the pursuit of a better quality of life for patients with acromegaly in that time she played a leading role in inventing our proprietary transient permeability enhancer tpe technology platform and developing our octreotide capsules product candidate we greatly appreciate her service and dedication and we welcome her forthcoming contributions as she rejoins the board i firmly believe in chiasmas vision of delivering increased convenience comfort and the potential for better symptom control to patients with acromegaly mamluk said i look forward to serving in an oversight capacity on both the chiasma ltd and chiasma inc boards of directors we have accomplished much during my tenure with the company and i am excited to build on those achievements in the years to come in mamluks new director role she will act as head of development on a parttime basis she will also have ongoing oversight of the companys israeli operations mamluk previously served as chiasmas chief development officer from march  to april  she also was the companys chief executive officer from april  to march  she held various roles of increasing responsibility including chief operating officer and vice president research and development from  through  she also served as a member of chiasmas board of directors from april  to march  in her time with chiasma mamluk has played a leading role in developing and is one of the primary inventors of the companys proprietary tpe technology platform mamluk previously worked for adnexus therapeutics where she established and led nonclinical research and development she received her ba and phd from hebrew university she also participated in a postdoctoral fellowship at boston childrens hospital  harvard medical school in the field of angiogenesis if you liked this article you might like what adam feuerstein got right and wrong about biotech stocks in  thestreets biotech columnist offers his own report card on biotech stocks adam feuerstein dec    am est  stocks under  set to soar these under stocks are within range of triggering breakout trades roberto pedone jun    pm edt chiasma chma stock plummets on disappointing fda letter chiasma chma stock is tanking this afternoon after the fda said a new drug application isnt ready for approval rachel graf apr    pm edt chiasma plunges after fda rejects application for growth disorder drug shares of chiasma are plunging this morning after the company said the fda rejected the companys application for approval of a proposed treatment of adult patients with a growth disorder the fly staff apr    am edt trending here is what jim cramer expects from facebooks earnings we found  products on amazon with inflated discount rates advanced micro devices could explode another  within hours chart stock futures rise on earnings beats from amd and boeing amd soars on stellar q results and upbeat guidance what wall streets saying advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers roni mamluk  roche diagnostics corporation  zoominfocom roni mamluk  waban ma  intelius sign in we found roni mamluk in waban ma roni mamluk intelius found that roni mamluk is a female between  and  years old from waban ma we have connected them to  addresses  phones and  relatives or associates get report now age roni mamluk is in her s roni has lived in waban ma stoneham ma cambridge ma roni mamluk zodiac signvirgo genderfemale professional status marketing owner at chiasma inc get report now want to know more about roni get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about roni or use our people search engine to find others get background check on roni mamluk get a criminal check on roni mamluk get a public record report on roni mamluk get a people search report on roni mamluk roni mamluks contact information known cities lived in find out where roni mamluk has lived as well as roni mamluks phone numbers and email addresses roni mamluk has lived in  states massachusetts address for roni mamluk  c r waban ma has lived in waban ma stoneham ma get full address report phone numbers associated with roni mamluk    newton center ma    cambridge ma    gaithersburg md get full phone report email addresses associated with roni mamluk rkcom rkcom ricom get email report roni mamluks professional information information regarding roni mamluks professional history find out previous places roni mamluk has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act roni mamluk has worked at  places company chiasma inc title marketing owner company chiasma inc title general manager and vice president research and development roni mamluks experience title marketing owner company chiasma inc job details at chiasma we are focused on improving the lives of patients suffering from orphan diseases by developing and ultimately commercializing novel oral therapies that are available today only by injection we are guided every day by our strongly held valuescompassion for the patients we serveinnovation in applying our proprietary transient permeability enhancer tpe® technology platform broadly to provide hope for patients and providersefficiency in managing our resources and investing in areas where we can have the greatest impactintegrity in the way we conduct research do business and communicate to our diverse audiences title general manager and vice president research and development company chiasma inc job details company size less than  mil additional professional information on roni mamluk see roni mamluks linkedin profile roni mamluks social network and potential email matches find out potential social network profiles and potential email usernamed for roni mamluk roni mamluks known social networks and potential email matches find all of roni mamluks social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches roni mamluk username matches ronimamluk mamlukroni ronimamluk mamlukroni ronimamluk mamlukroni ronimamluk mamlukroni rmamluk popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches r mamluk intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here roni mamluk  cambridge ma  intelius sign in we found roni mamluk in cambridge ma roni mamluk intelius found that roni mamluk is a female between  and  years old from cambridge ma we have connected them to  addresses  phones and  relatives or associates get report now age roni mamluk is in her s roni has lived in cambridge ma belmont ma stoneham ma roni mamluk zodiac signvirgo genderfemale professional status marketing owner at chiasma inc get report now want to know more about roni get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about roni or use our people search engine to find others get background check on roni mamluk get a criminal check on roni mamluk get a public record report on roni mamluk get a people search report on roni mamluk roni mamluks contact information known cities lived in find out where roni mamluk has lived as well as roni mamluks phone numbers and email addresses roni mamluk has lived in  states massachusetts address for roni mamluk  c s cambridge ma has lived in cambridge ma belmont ma get full address report phone numbers associated with roni mamluk    newton center ma    cambridge ma    gaithersburg md get full phone report email addresses associated with roni mamluk rkcom rkcom ricom get email report roni mamluks professional information information regarding roni mamluks professional history find out previous places roni mamluk has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act roni mamluk has worked at  places company chiasma inc title marketing owner company chiasma inc title general manager and vice president research and development roni mamluks experience title marketing owner company chiasma inc job details at chiasma we are focused on improving the lives of patients suffering from orphan diseases by developing and ultimately commercializing novel oral therapies that are available today only by injection we are guided every day by our strongly held valuescompassion for the patients we serveinnovation in applying our proprietary transient permeability enhancer tpe® technology platform broadly to provide hope for patients and providersefficiency in managing our resources and investing in areas where we can have the greatest impactintegrity in the way we conduct research do business and communicate to our diverse audiences title general manager and vice president research and development company chiasma inc job details company size less than  mil additional professional information on roni mamluk see roni mamluks linkedin profile roni mamluks social network and potential email matches find out potential social network profiles and potential email usernamed for roni mamluk roni mamluks known social networks and potential email matches find all of roni mamluks social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches roni mamluk username matches ronimamluk mamlukroni ronimamluk mamlukroni ronimamluk mamlukroni ronimamluk mamlukroni rmamluk popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches r mamluk intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here